Headlines

Online Lens Replacement Company Raises $3M

8 investors participated in the round.

Published

8 years ago

November 6, 2018

INVISION Staff

Online lens replacement startup Lensabl has raised $3 million in funding, according to Crunchbase.

The investment round was led by Rogue Venture Partners. Eight investors participated in total.

TechCrunch quoted Lensabl CEO Andrew Bilinsky saying: “We are the preferred prescription provider of Snapchat Spectacles. [And] we are already talking to and partnering with a variety of brands to start and scale their prescription operations [and] really scale our direct to consumer lens business.”

Lensabl launched its online prescription lens replacement service, which targets consumers directly, in late 2016. The site offers clear, tinted and transitional prescription lenses for eyeglasses and sunglasses.

The founders had started out selling frames in 2013 in a model not unlike that of online eyewear giant Warby Parker. But customers started requesting the ability to order frames with the proper prescription lenses, and they realized they’d happened upon an industry pain point.

In addition to Rogue, investors included Watertower Ventures, Luma Launch, CrowdSmart, Cherry Tree Investments, Birchmere Ventures, Aspect Ventures and Amplify.LA.

Cherry Optical Lab

Rooted in the Pursuit of Excellence.

Cherry Optical Lab is a family-owned, Independent wholesale optical Laboratory that produces lenses 24 hours a day, 5+ days a week, and is obsessed with making two things:

1. The world’s best lenses

2. The world’s Happiest Humans*

*Our team members, our customers, and their customers

We boldly believe that our job is to serve Eye Care Professionals and deliver excellence for patients, regardless of the prescription. That’s why we offer accelerated turnaround times for high-quality, high-standard lenses made by craftspeople who hold the same certifications as opticians.

All this is our effort to give Eye Care Professionals more ways to say “Yes” to their patients.

Learn More.